What Is the Risk of Reactivation in Patients with Resolved and Past HBV Infection During Immunosuppressive Therapy If HBV-DNA Negative before Treatment?
Yıl: 2021 Cilt: 32 Sayı: 3 Sayfa Aralığı: 294 - 301 Metin Dili: İngilizce DOI: 10.5152/tjg.2021.201131 İndeks Tarihi: 27-05-2022
What Is the Risk of Reactivation in Patients with Resolved and Past HBV Infection During Immunosuppressive Therapy If HBV-DNA Negative before Treatment?
Öz: Background: Reactivation of Hepatitis B (HBVr) related to immunosuppressive drug therapy (ISDT) in patients with resolved and past
infection is a challenging entity. The number of prospective long-term studies is limited.
Methods: Two groups of patients with resolved and past HBV infection were analyzed prospectively. The patients were further categorized as 266 patients receiving ISDT (group 1) and 246 patients receiving antineoplastic therapy (group 2).
Results: We did not detect any cases of HBVr among 108 patients receiving rituximab (71 of which were anti-HBc positive only),
111 patients receiving tumor necrosis factor inhibitors (66 of which were anti-HBc positive only), and 42 patients receiving high-dose
glucocorticoids for more than 4 weeks (24 of which were anti-HBc positive only) during a mean follow-up time of more than 24 months.
Subgroup analysis of the anti-HBs (+) patients showed that in group A (anti-HBs >1000 mIU/mL) the antibody levels did not change; in
group B (anti-HBs between 100 and 1000 mIU/mL) the antibody levels changed non-significantly (P = .25), and in Group C (anti-HBs
between 0 and 100 mIU/mL) the antibody levels declined significantly (P = .002). Furthermore, 16 patients in Group C had an anti-HBs
loss during follow-up, but no HBVr was detected.
Conclusion: The risk of HBVr by immunosuppressive therapy in this group may be lower than that suspected in the literature and antiHBs levels may not seem to correlate with the risk of reactivation.
Anahtar Kelime: Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık
- 1. Nassal M. HBV cccDNA: viral persistence reservoir and key obstacle for a cure of chronic hepatitis B. Gut. 2015;64(12):1972-1984. [CrossRef]
- 2. Hoofnagle JH. Reactivation of hepatitis B. Hepatology. 2009;49(5 Suppl):S156-S165. [CrossRef]
- 3. Howlader N, Noone AM, Krapcho M, et al. SEER Cancer Statistics Review, 1975-2014. Bethesda: National Cancer Institute; 2017.
- 4. Perrillo RP, Gish R, Falck-Ytter YT. American Gastroenterological Association Institute technical review on prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy. Gastroenterology. 2015;148(1):221.e3-244.e3. [CrossRef]
- 5. Terrault NA, Lok ASF, McMahon BJ, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology. 2018;67(4):1560-1599. [CrossRef]
- 6. Bel’eed K, Wright M, Eadington D, Farr M, Sellars L. Vaccination against hepatitis B infection in patients with end stage renal disease. Postgrad Med J. 2002;78(923):538-540. [CrossRef]
- 7. Pei SN, Ma MC, Wang MC, et al. Analysis of hepatitis B surface antibody titers in B cell lymphoma patients after rituximab therapy. Ann Hematol. 2012;91(7):1007-1012. [CrossRef]
- 8. Cho Y, Yu SJ, Cho EJ, et al. High titers of anti-HBs prevent rituximab-related viral reactivation in resolved hepatitis B patient with non-Hodgkin’s lymphoma. J Med Virol. 2016;88(6):1010-1017. [CrossRef]
- 9. Pattullo V. Prevention of hepatitis B reactivation in the setting of immunosuppression. Clin Mol Hepatol. 2016;22(2):219-237. [CrossRef]
- 10. Pérez-Alvarez R, Díaz-Lagares C, García-Hernández F, et al. Hepatitis B virus (HBV) reactivation in patients receiving tumor necrosis factor (TNF)-targeted therapy: analysis of 257 cases. Medicine. 2011;90(6):359-371. [CrossRef]
- 11. Lau GK. Hepatitis B reactivation after chemotherapy: two decades of clinical research. Hepatol Int. 2008;2(2):152-162. [CrossRef]
- 12. Huang YH, Hsiao LT, Hong YC, et al. Randomized controlled trial of entecavir prophylaxis for rituximab-associated hepatitis B virus reactivation in patients with lymphoma and resolved hepatitis B. J Clin Oncol. 2013;31(22):2765-2772. [CrossRef]
- 13. Hsu C, Tsou HH, Lin SJ, et al. Chemotherapy-induced hepatitis B reactivation in lymphoma patients with resolved HBV infection: a prospective study. Hepatology. 2014;59(6):2092-2100. [CrossRef]
- 14. Wang Q, Klenerman P, Semmo N. Significance of anti-HBc alone serological status in clinical practice. Lancet Gastroenterol Hepatol. 2017;2(2):123-134. [CrossRef]
- 15. Katz L, Strong DM, Tegtmeier G, Stramer S. Performance of an algorithm for the reentry of volunteer blood donors deferred due to false-positive test results for antibody to hepatitis B core antigen. Transfusion. 2008;48(11):2315-2322. [CrossRef]
- 16. Hoeks MPA, Kranenburg FJ, Middelburg RA, van Kraaij MGJ, Zwaginga JJ. Impact of red blood cell transfusion strategies in haemato-oncological patients: a systematic review and meta-analysis. Br J Haematol. 2017;178(1):137-151. [CrossRef]
- 17. Gessoni G, Beggio S, Barin P, et al. Significance of anti-HBc only in blood donors: a serological and virological study after hepatitis B vaccination. Blood Transfus. 2014;12(Suppl 1):s63-s68. [CrossRef]
- 18. Dienstag JL. Hepatitis B virus infection. N Engl J Med. 2008;359(14):1486-1500. [CrossRef]
- 19. Di Marco V, Marzano A, Lampertico P, et al. Clinical outcome of HBeAg-negative chronic hepatitis B in relation to virological response to lamivudine. Hepatology. 2004;40(4):883-891. [CrossRef]
- 20. Vassilopoulos D, Apostolopoulou A, Hadziyannis E, et al. Longterm safety of anti-TNF treatment in patients with rheumatic diseases and chronic or resolved hepatitis B virus infection. Ann Rheum Dis. 2010;69(7):1352-1355. [CrossRef]
- 21. Shirvani-Dastgerdi E, Winer BY, Celià-Terrassa T, et al. Selection of the highly replicative and partially multidrug resistant rtS78T HBV polymerase mutation during TDF-ETV combination therapy. J Hepatol. 2017;67(2):246-254. [CrossRef]
- 22. Kay A, Zoulim F. Hepatitis B virus genetic variability and evolution. Virus Res. 2007;127(2):164-176. [CrossRef]
- 23. Allweiss L, Dandri M. The role of cccDNA in HBV maintenance. Viruses. 2017;9(6):156. [CrossRef]
- 24. Getts DR, Shankar S, Chastain EM, et al. Current landscape for T-cell targeting in autoimmunity and transplantation. Immunotherapy. 2011;3(7):853-870. [CrossRef]
- 25. Seto WK, Chan TS, Hwang YY, et al. Hepatitis B reactivation in patients with previous hepatitis B virus exposure undergoing rituximab-containing chemotherapy for lymphoma: a prospective study. J Clin Oncol. 2014;32(33):3736-3743. [CrossRef]
- 26. Loras C, Gisbert JP, Saro MC, et al. Impact of surveillance of hepatitis B and hepatitis C in patients with inflammatory bowel disease under anti-TNF therapies: multicenter prospective observational study (REPENTINA 3). J Crohns Colitis. 2014;8(11):1529-1538. [CrossRef]
- 27. Tozun N, Ozdogan O, Cakaloglu Y, et al. Seroprevalence of hepatitis B and C virus infections and risk factors in Turkey: a fieldwork TURHEP study. Clin Microbiol Infect. 2015;21(11):1020-1026. [CrossRef]
- 28. Su YC, Lin PC, Yu HC, Wu CC. Hepatitis B virus reactivation in patients with resolved hepatitis B virus infection receiving chemotherapy or immunosuppressive therapy. Eur J Gastroenterol Hepatol. 2018;30(8):925-929. [CrossRef]
| APA | Tokmak S, GÜMÜRDÜLÜ Y, ARSLAN D, kara o, güzel a (2021). What Is the Risk of Reactivation in Patients with Resolved and Past HBV Infection During Immunosuppressive Therapy If HBV-DNA Negative before Treatment?. , 294 - 301. 10.5152/tjg.2021.201131 |
| Chicago | Tokmak Salih,GÜMÜRDÜLÜ YÜKSEL,ARSLAN DIDEM,kara oğuz,güzel ahmet barış What Is the Risk of Reactivation in Patients with Resolved and Past HBV Infection During Immunosuppressive Therapy If HBV-DNA Negative before Treatment?. (2021): 294 - 301. 10.5152/tjg.2021.201131 |
| MLA | Tokmak Salih,GÜMÜRDÜLÜ YÜKSEL,ARSLAN DIDEM,kara oğuz,güzel ahmet barış What Is the Risk of Reactivation in Patients with Resolved and Past HBV Infection During Immunosuppressive Therapy If HBV-DNA Negative before Treatment?. , 2021, ss.294 - 301. 10.5152/tjg.2021.201131 |
| AMA | Tokmak S,GÜMÜRDÜLÜ Y,ARSLAN D,kara o,güzel a What Is the Risk of Reactivation in Patients with Resolved and Past HBV Infection During Immunosuppressive Therapy If HBV-DNA Negative before Treatment?. . 2021; 294 - 301. 10.5152/tjg.2021.201131 |
| Vancouver | Tokmak S,GÜMÜRDÜLÜ Y,ARSLAN D,kara o,güzel a What Is the Risk of Reactivation in Patients with Resolved and Past HBV Infection During Immunosuppressive Therapy If HBV-DNA Negative before Treatment?. . 2021; 294 - 301. 10.5152/tjg.2021.201131 |
| IEEE | Tokmak S,GÜMÜRDÜLÜ Y,ARSLAN D,kara o,güzel a "What Is the Risk of Reactivation in Patients with Resolved and Past HBV Infection During Immunosuppressive Therapy If HBV-DNA Negative before Treatment?." , ss.294 - 301, 2021. 10.5152/tjg.2021.201131 |
| ISNAD | Tokmak, Salih vd. "What Is the Risk of Reactivation in Patients with Resolved and Past HBV Infection During Immunosuppressive Therapy If HBV-DNA Negative before Treatment?". (2021), 294-301. https://doi.org/10.5152/tjg.2021.201131 |
| APA | Tokmak S, GÜMÜRDÜLÜ Y, ARSLAN D, kara o, güzel a (2021). What Is the Risk of Reactivation in Patients with Resolved and Past HBV Infection During Immunosuppressive Therapy If HBV-DNA Negative before Treatment?. Turkish Journal of Gastroenterology, 32(3), 294 - 301. 10.5152/tjg.2021.201131 |
| Chicago | Tokmak Salih,GÜMÜRDÜLÜ YÜKSEL,ARSLAN DIDEM,kara oğuz,güzel ahmet barış What Is the Risk of Reactivation in Patients with Resolved and Past HBV Infection During Immunosuppressive Therapy If HBV-DNA Negative before Treatment?. Turkish Journal of Gastroenterology 32, no.3 (2021): 294 - 301. 10.5152/tjg.2021.201131 |
| MLA | Tokmak Salih,GÜMÜRDÜLÜ YÜKSEL,ARSLAN DIDEM,kara oğuz,güzel ahmet barış What Is the Risk of Reactivation in Patients with Resolved and Past HBV Infection During Immunosuppressive Therapy If HBV-DNA Negative before Treatment?. Turkish Journal of Gastroenterology, vol.32, no.3, 2021, ss.294 - 301. 10.5152/tjg.2021.201131 |
| AMA | Tokmak S,GÜMÜRDÜLÜ Y,ARSLAN D,kara o,güzel a What Is the Risk of Reactivation in Patients with Resolved and Past HBV Infection During Immunosuppressive Therapy If HBV-DNA Negative before Treatment?. Turkish Journal of Gastroenterology. 2021; 32(3): 294 - 301. 10.5152/tjg.2021.201131 |
| Vancouver | Tokmak S,GÜMÜRDÜLÜ Y,ARSLAN D,kara o,güzel a What Is the Risk of Reactivation in Patients with Resolved and Past HBV Infection During Immunosuppressive Therapy If HBV-DNA Negative before Treatment?. Turkish Journal of Gastroenterology. 2021; 32(3): 294 - 301. 10.5152/tjg.2021.201131 |
| IEEE | Tokmak S,GÜMÜRDÜLÜ Y,ARSLAN D,kara o,güzel a "What Is the Risk of Reactivation in Patients with Resolved and Past HBV Infection During Immunosuppressive Therapy If HBV-DNA Negative before Treatment?." Turkish Journal of Gastroenterology, 32, ss.294 - 301, 2021. 10.5152/tjg.2021.201131 |
| ISNAD | Tokmak, Salih vd. "What Is the Risk of Reactivation in Patients with Resolved and Past HBV Infection During Immunosuppressive Therapy If HBV-DNA Negative before Treatment?". Turkish Journal of Gastroenterology 32/3 (2021), 294-301. https://doi.org/10.5152/tjg.2021.201131 |
